Rycarfa vet.
Active substance
ATC code
Species
Dogs and cats.
Indications
Dogs: For the control of post-operative pain and inflammation following orthopaedic and soft tissue (including intraocular) surgery.
Cats: For the control of post-operative pain following surgery.
Dose to be administered and administration route
For intravenous or subcutaneous administration
Dogs: The recommended dosage is 4.0 mg carprofen/kg bodyweight (1 ml/12.5 kg bodyweight). The product is best given pre-operatively, either at the time of premedication or induction of anaesthesia.
Cats: The recommended dosage is 4.0 mg/kg (0.24 ml/3.0 kg bodyweight), best given pre-operatively at the time of induction of anaesthesia. The use of a 1 ml graduated syringe is recommended to measure the dose accurately.
Clinical trial evidence in dogs and cats suggests only a single dose of carprofen is required in the first 24 hours perioperatively; if further analgesia is required in this period a half dose (2 mg/kg) of carprofen may be given to dogs (but not to cats) as necessary.
The weight of treated animals should be accurately determined before administration.
In dogs, to extend analgesic and anti-inflammatory cover post-operatively, parenteral therapy may be followed with carprofen tablets at 4 mg/kg/day for up to 5 days.
For administration of the product a 21-gauge needle should be used.
The cap can be punctured up to 20 times. When puncturing more than 20 times, use a draw-off needle.
Adverse reactions
Typical undesirable effects associated with NSAIDs such as vomiting, soft faeces/diarrhoea, faecal occult blood, loss of appetite and lethargy have been reported. These adverse reactions occur generally within the first treatment week and are in most cases transient and disappear following termination of the treatment but in very rare cases may be serious or fatal.
If adverse reactions occur, use of the product should be stopped and the advice of a veterinarian should be sought.
As with other NSAIDs there is a risk of rare renal or idiosyncratic hepatic adverse events.
Occasionally reactions at the injection site may be observed following subcutaneous injection.
The frequency of adverse reactions is defined using the following convention:
- very common (more than 1 in 10 animals treated displaying adverse reaction(s))
- common (more than 1 but less than 10 animals in 100 animals treated)
- uncommon (more than 1 but less than 10 animals in 1,000 animals treated)
- rare (more than 1 but less than 10 animals in 10,000 animals treated)
- very rare (less than 1 animal in 10,000 animals treated, including isolated reports).
Similar products
Showing 3 of 3 results
Rycarfa vet.
Rycarfa vet.
